Respected Neuropathologist Appointed New Editor-in-Chief Of The American Journal Of Pathology
AJP, published by Elsevier, is owned by and is the official journal of ASIP. ASIP's Executive Officer, Mark E. Sobel, M.D., Ph.D., summarized ASIP's selection of Dr. Roth by saying, "Dr. Roth is well recognized within the academic pathology community as well as the broad discipline of experimental biology, from which AJP draws its authors. Dr. Roth has chosen ASIP Past President and fellow AJP Associate Editor Martha Furie, Ph.D., Professor in the Center for Infectious Diseases at Stony Brook University, as his Senior Associate Editor. With the appointments of Drs. Roth and Furie, the Society leadership looks forward with excitement to what this team will bring to the editorial direction of ASIP's flagship journal, AJP, ensuring a synergistic relationship between the Journal and the Society."
Jay M. McDonald, M.D., himself former UAB Chair of Pathology (1990 to 2008) and Editor-in-Chief of AJP (2003 to 2008), praised ASIP's choice: "Dr. Roth is an outstanding academic pathologist, excelling in research, service, and teaching. He will be an outstanding Editor-in-Chief for AJP."
About The American Society for Investigative Pathology
The American Society for Investigative Pathology (ASIP) is a society of biomedical scientists who investigate mechanisms of disease. Investigative pathology is an integrative discipline that links the presentation of disease in the whole organism to its fundamental cellular and molecular mechanisms. It uses a variety of structural, functional, and genetic techniques and ultimately applies research findings to the diagnosis and treatment of diseases. ASIP advocates for the practice of investigative pathology and fosters the professional career development and education of its members. ( http://www.asip.org)
About The American Journal of Pathology The American Journal of Pathology ( http://ajp.amjpathol.org), official journal of the American Society for Investigative Pathology, seeks to publish high-quality, original papers on the cellular and molecular biology of disease. The editors accept manuscripts that advance basic and translational knowledge of the pathogenesis, classification, diagnosis, and mechanisms of disease, without preference for a specific analytic method. High priority is given to studies on human disease and relevant experimental models using cellular, molecular, animal, biological, chemical, and immunological approaches in conjunction with morphology. The leading global forum for reporting quality original research on cellular and molecular mechanisms of disease, The American Journal of Pathology is the most highly cited journal in Pathology - over 38,000 cites in 2011 - with an Impact Factor of 4.890 according to 2011 Journal Citation Reports ® Thomson Reuters. About ElsevierSelect the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
